BEVERLY HUTZLER: Open Payments
NPI 1235779299 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$943 in 31 payments from 16 companies in 2025. Trend: 2023 $329 · 2024 $447 · 2025 $943
Food & beverage: $943
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 4 | $178 |
| Eisai Inc. | 3 | $176 |
| Genentech USA, Inc. | 4 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $93 |
| AstraZeneca Pharmaceuticals LP | 3 | $78 |
| Janssen Biotech, Inc. | 2 | $59 |
| ABBVIE INC. | 2 | $50 |
| ARGENX US, INC. | 1 | $31 |
| Astellas Pharma US Inc | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $28 |
Products named: Lenvima, KEYTRUDA, LYNPARZA, VONVENDI, Polivy, ELAHERE, HYQVIA, DARZALEX.
Industry payments across TX — which companies pay providers there.
